Built to help voters quickly verify how officials vote — district first, party second. All information is sourced from official public records.
HR. 1405 · 119th Congress

Enhancing Domestic Drug Manufacturing Competitiveness Act

In committee

This bill has not become law. Status shown reflects the latest official action.

See what this could mean for your district

Save your district in Account to view district-specific context for this bill.

Bill details

Introduced: 2/18/2025
Status: Referred to the House Committee on Energy and Commerce.
Bill ID: 119hr1405
Latest action: Referred to the House Committee on Energy and Commerce.

Summary

Introduced in House

Enhancing Domestic Drug Manufacturing Competitiveness Act This bill requires the Government Accountability Office (GAO) to study and report to Congress on key regulatory barriers to pharmaceutical manufacturing in the United States. Specifically, GAO must identify and assess, including by engaging stakeholders, barriers that impede expansion or siting of pharmaceutical manufacturing facilities in the United States or make the United States less competitive than other countries as a location for such facilities. GAO must consider (1) whether environmental or other regulations significantly delay and increase the cost of expanding or siting pharmaceutical manufacturing facilities in the United States; (2) the potential impact of environmental and other regulations on pharmaceutical supply chain resiliency; and (3) specific actions for regulators to address the identified barriers. Finally, the report must include recommendations for streamlining regulatory barriers and facilitating technological solutions to foster U.S. pharmaceutical manufacturing.

Source: BILLSUM · Summary date: 2/18/2025

District impact notes

1 notes
NEUTRAL
3/22/2026

The Enhancing Domestic Drug Manufacturing Competitiveness Act requires a study on regulatory barriers affecting pharmaceutical manufacturing in the U.S. • This study could identify local challenges related to pharmaceutical manufacturing that may impact job opportunities in the area. • The findings may inform local institutions about potential changes in regulations that could affect public health initiatives or local supply chains. • There may be concerns about balancing environmental regulations with the need to enhance manufacturing competitiveness, which could lead to discussions on policy priorities. AI-generated from official bill summary and plain-English note; verify with official text.

Related votes

Roll calls that reference this bill in official data.

0 roll calls
No related roll calls found yet for this bill.

Primary sources

Official links to verify details. (No interpretation.)

Summary source label: BILLSUM
About this data
  • OurCongress is non-partisan by design. We do not add political interpretation or advocacy.
  • Bill data and official summaries come from GovInfo and Congress.gov. Some bills do not have published summaries yet.
  • District impact notes (when shown) are AI-generated from official bill metadata/summaries to improve readability. They are not official government language.
  • This page updates automatically via a daily ingestion pipeline.

About this data

Non-partisan by design
OurCongress provides plain-English context without endorsements, political interpretation, or advocacy.
Official sources
Data is sourced from official government records (e.g., Congress.gov, GovInfo, Clerk of the House, and the U.S. Senate).
AI-generated text
Some sections may be AI-generated from official summaries/metadata to help readability. AI output can be imperfect—verify with primary sources.
Last updated: 3/22/2026Source: BILLSUMBill: 119hr1405Learn more →